Xeris Biopharma Holdings, Inc. announced a collaboration agreement with Merck, with an option to license Xeris' suspension-based formulation technology, XeriJect, for use with undisclosed monoclonal antibodies (mAbs) for the purpose of engineering ultra-high concentration, ready-to-use formulations. Terms of the agreement were not disclosed.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.89 USD | +1.61% | +8.00% | -19.57% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.57% | 280M | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
+8.08% | 167B | |
-3.40% | 157B |
- Stock Market
- Equities
- XERS Stock
- News Xeris Biopharma Holdings, Inc.
- Xeris Pharmaceuticals Enters Collaboration Agreement With Merck